Nasdaq GlobeNewswire

Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS

Del

Results published in Expert Review of Cardiovascular Therapy

CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced completion of a new study to assess the burden of people living with Familial Chylomicronemia Syndrome (FCS) and its impact on their daily lives. Results from the study known as Re-FOCUS were published on June 11, 2018 in the peer-reviewed journal Expert Review of Cardiovascular Therapy .

Twenty-two people with FCS participated in the Re-FOCUS survey. They were asked to assess the number and severity of a range of symptoms and daily life measures affected by FCS. The web-based global study was conducted among people with FCS treated with volanesorsen, Akcea's investigational therapy currently under regulatory review in the US, EU and Canada.

"FCS is an ultra-rare disease that has not been widely studied. This landmark study represents an important step in our efforts to identify and quantify the many ways that FCS can affect the physical, functional and emotional health of people living with FCS," said Michael W. Stevenson, R.Ph., Ph.D., global vice president, medical affairs at Akcea. "The Re-FOCUS study provides helpful, new information as we work to design and validate a tool that can accurately evaluate changes in disease burden with therapeutic intervention." 

The Re-FOCUS study represents another milestone in Akcea's ongoing efforts to understand the impact of FCS. In October 2017, Akcea announced results of the IN-FOCUS study, a survey of 166 people with FCS in 10 countries. The data provided new insight on the disease burden, including cognitive, emotional, and physical impairments that can affect daily life as well as the risk of recurrent, potentially fatal, acute pancreatitis.

"For people living with FCS, it impacts every part of daily life, often making it difficult to work, care for other family members or even join in life events with family and friends. Studies like IN-FOCUS and Re-FOCUS can enable patients and caregivers around the world to better understand and communicate about the devastating effects of this rare disease," said Lindsey Sutton, co-president of the FCS Foundation.

"We are working to increase understanding of FCS, through our clinical programs, scientific communications, and by bringing forward the voices of those who live with this disease," said Molly Harper, vice president, and global franchise head, cardiometabolics. "We would like to thank the FCS Foundation as well as all of the patients, caregivers and clinicians who participated in or supported this groundbreaking work, which will help build awareness and improve quality of care for patients with FCS and potentially other rare diseases."

ABOUT FCS
FCS is an ultra-rare disease caused by impaired function of the enzyme lipoprotein lipase (LPL) and characterized by severe hypertriglyceridemia (>880mg/dL) and a risk of unpredictable and potentially fatal acute pancreatitis. Because of limited LPL function, people with FCS cannot breakdown chylomicrons, lipoprotein particles that are 90% triglycerides. In addition to pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage. They can experience daily symptoms including abdominal pain, generalized fatigue and impaired cognitions that affect their ability to work. People with FCS also report major emotional and psychosocial effects including anxiety, social withdrawal, depression and brain fog. There is no effective therapy for FCS currently available. Additional information on FCS is available at www.fcsfocus.com, and through the FCS Foundation at http://www.livingwithfcs.org and the LPLD Alliance at www.lpldalliance.org. For a full list of organizations supporting the FCS community worldwide, please click here.

ABOUT AKCEA THERAPEUTICS, INC.
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including TEGSEDITM (inotersen), WAYLIVRATM (volanesorsen), AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. TEGSEDI is under regulatory review in the U.S., EU and Canada for the treatment of people with hereditary transthyretin amyloidosis (hATTR). WAYLIVRA is under regulatory review in the U.S., EU and Canada for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com.

Forward Looking Statement
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc., and the therapeutic and commercial potential of WAYLIVRATM (volanesorsen) and other products in development. Any statement describing Akcea's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in its annual report on Form 10-K for the year ended December 31, 2017, which is on file with the SEC.

In this press release, unless the context requires otherwise, "Ionis," "Akcea," "Company," "Companies," "we," "our," and "us" refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.

Ionis Pharmaceuticals(TM) is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics(TM), TEGSEDITM and WAYLIVRATM are trademarks of Akcea Therapeutics, Inc.

Akcea Media and Investor Contact:
Kathleen Gallagher                                                                         
Head of Communications and Investor Relations 
(617)-207-8509
kgallagher@akceatx.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Akcea Therapeutics, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Quantenna and Telefónica Reinforce Strategic Partnership with New Portfolio of 8x8 MIMO Wi-Fi 6 Products12.12.2018 23:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Quantenna Communications, Inc. (NASDAQ: QTNA) is further strengthening its strategic partnership with Telefónica. Through a long history of cooperation, the two companies have developed multiple generations of best-in-class products including gateways, repeaters and set-top boxes deployed in Europe and Latin America. Leveraging Quantenna’s 8x8 QSR10GU-AX, Telefónica is delivering a new portfolio of high-end fiber gateways and repeaters. The Wi-Fi 6 compliant QSR10GU-AX provides integrated dual-band, dual-concurrent 2.4GHz and 5GHz functionality in the same chipset, supporting up to a maximum speed of 10Gbps and 12 simultaneous streams. Thanks to its “Always-On DFS” feature, the QSR10GU-AX offers enhanced radar detection and spectrum analyzer capabilities with wide frequency range analysis. The QSR10GU-AX also supports advanced MU-MIMO, allowing for transmission to multiple devices at the same time, and providing higher throughput, inc

Improved Accuracy and Speed for Disease Research, Two Genomic Companies Integrate Kits and Software to Enable Deep Exploration of Epigenetic Data12.12.2018 21:16Pressemelding

OnRamp’s ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- OnRamp BioInformatics, a genomics company focused on scientist-friendly bioinformatics software solutions, today announced they are working with Active Motif to improve accuracies in data analysis for ChIP-Seq experiments. OnRamp’s flagship software, ROSALIND, provides a point-and-click experience to speed up and simplify the process of genomic data analysis from experiment setup to QC and interactive data visualization to interpretation. With this integration, researchers will now benefit from an optimized analysis that includes the unique characteristics of Active Motif kits and antibodies, including Unique Molecular Identifiers (UMI) and spike-in solutions. Active Motif customers will now be able to rapidly interpret their data with ROSALIND’s identificati

Markforged launches H13 tool steel for high-strength, high-temp tooling applications12.12.2018 15:00Pressemelding

New material for Metal X 3D printing system is first of many WATERTOWN, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Markforged, the Boston-area 3D printer company transforming manufacturing, today announced the launch of H13 tool steel for the Metal X, the world’s leading desktop-sized metal printer with over 150 systems shipped since March 2018. The expansion into H13 will enable customers to print parts in high-strength, high-temperature applications such as metal forming tools, dies and punches, and hardened inserts for fixtures, and even injection molds with conformal cooling channels. To learn more about H13 tool steel and place an order, please visit http://markforged.com/h13 “We designed the Metal X system to change the way things are made, and the launch of H13 is the next step down that path,” said Jon Reilly, Markforged VP of product. “For manufacturers of high-volume plastic parts this is a game changer, significantly accelerating the speed at which they can bring new products

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease12.12.2018 14:30Pressemelding

Bermekimab Therapy Rapidly and Significantly Reduces Disease AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has completed and the study met all primary and secondary endpoints. Thirty eight patients in two treatment groups received a low (n=10) or high (n=28) dose of bermekimab once weekly for either a 4 or 7-week treatment regimen, respectively. Statistically significant improvement was seen for all efficacy endpoints in the high dose group; and a significant dose response for the high dose compared to low dose group was observed for key endpoints, including the Eczema Area and Severity Index (EASI), Global Individual Sign Score (GISS), Patient Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), and SCORing Atopic Dermatitis (SCORAD). While clinically and statistically significant

Cisco and UBS to host ESG Conference Call/Webcast for the Financial Community on 12/17/1812.12.2018 14:00Pressemelding

SAN JOSE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Cisco and UBS will host an ESG (Environmental, Social and Governance) Conference Call/Webcast for the Financial Community, at 11:00 a.m. ET/ 4:00 p.m. GMT on Monday, December 17, 2018. Kathy Mulvany, Cisco’s VP of Corporate Affairs, and Darrel Stickler, Cisco’s Environmental Sustainability Lead, will provide an overview of Cisco’s Corporate Social Responsibility (CSR) strategy, priorities and goals, and explain why Cisco’s CSR initiatives play an important role in overall shareholder value creation. The call will be hosted by John Roy, Ph.D., UBS IT Hardware, Networking & Services Analyst, and Julie Hudson, CFA, and Victoria Kalb, UBS Global ESG & Sustainability Analysts. Interested parties can participate by dialing toll-free: 800 694 5649 or international: +1 303 223 2687, Code: 21910788, or listening to the webcast at investor.cisco.com. Further information and Cisco’s 2018 CSR Report can be found at csr.cisco.com About Cisco Cisco

Standard Lithium Makes First Pilot-Scale High Purity Lithium Carbonate and Commissions Crystallisation Pilot Prototype12.12.2018 09:01Pressemelding

VANCOUVER, British Columbia, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTC-Nasdaq Intl. Designation: STLHF) (FRA: S5L), is pleased to announce that the Company has completed the commissioning process for its prototype crystallisation pilot plant and has produced its first quantity of high purity (>99.1%) lithium carbonate. The Company, via its technology partners, is currently designing and fabricating both halves of its full-scale Pilot Plant; the Lithium Extraction Pilot Plant is being designed and built by Zeton Inc. in Burlington, Ontario, Canada; the Lithium Carbonate Crystallisation Pilot Plant is being designed and built by Saltworks Technologies Inc., at their facility in Richmond, British Columbia, Canada. Both parts of the Pilot Plant are based on Standard Lithium’s proprietary technology. The newly-constructed crystallisation pilot prototype was operated using a relatively ‘impure’ feed solution similar to, but

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom